drugset / Trial / NCT00379067
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Phase 4
Completed
882 enrolled
Astellas Pharma Inc
Astellas Pharma Europe Ltd. · collabBoehringer Ingelheim · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
Timeline
- Start
- 2005-10
- Primary completion
- 2006-11
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tamsulosin | Other / unclassified | 0.4 mg | — |